Gradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation System
PARIS, May 19, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today the company's pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an expedited review pathway for devices that have the potential to provide more effective treatment for life-threatening or debilitating conditions and meet FDA's rigorous standards for safety and efficacy.
The Gradient Denervation System is a novel technology intended to treat patients with pulmonary hypertension and associated heart failure. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures.
The PreVail-PH2 Early Feasibility Study is enrolling patients with pulmonary hypertension due to left-sided heart disease, classified by the World Health Organization (WHO) as Group 2 Pulmonary Hypertension. As many as two-thirds of heart failure patients around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalization. There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients.
'We are thrilled with this positive feedback from FDA. The granting of Breakthrough Device Designation marks another important milestone for our pulmonary denervation clinical development program,' said Martin Grasse, Chief Executive Officer of Gradient. 'We remain focused on completion of our early feasibility study as a crucial first step toward developing a targeted treatment option with the potential to improve outcomes and quality of life for these underserved patients.'
About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use.
For more information, please visit: https://www.gradientdenervation.com.
CONTACT: Media Contact info@gradientdenervation.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
34 minutes ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
New York Post
4 hours ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
Yahoo
5 hours ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
